Inflammatory bowel disease — Crohn's and ulcerative colitis — has drawn growing HBOT research interest. The picture is mixed. One specific subset shows a real signal, but broader use does not.
This page lays out where the data is strongest and where the marketing gets ahead. The honest read up front: perianal fistula in Crohn's may benefit, severe colitis flares may not.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for IBD |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for IBD |
| Insurance coverage | Out-of-pocket only at most clinics |
| Typical out-of-pocket | $6,000-$12,000 for a 40-session course |
| Evidence grade | Mixed — signal in perianal Crohn's, negative in severe UC |
The evidence
IBD HBOT research breaks into two camps. Perianal fistula in Crohn's has the cleanest positive signal. Severe colitis flares have a negative randomized trial.
The Dulai and colleagues 2014 systematic review, PMID 24738651 pooled the early IBD HBOT literature. The authors found HBOT was relatively safe and potentially helpful for some IBD presentations. The review called for randomized trials to confirm.
The Lansdorp HOT-TOPIC pilot 2021, PMID 35146959 treated 20 Crohn's patients with therapy-refractory perianal fistulas using 40 sessions of HBOT. At week 16, the perianal disease activity index dropped in 13 of 20 patients to inactive levels. Clinical, radiologic, and biochemical markers all improved.
The Lansdorp 2022 HOT-TOPIC one-year follow-up reported on the same 20 patients at 60 weeks. Clinical and radiologic gains held. Biochemical and quality-of-life gains seen at week 16 did not hold to 60 weeks.
The Pagoldh and colleagues 2013 ulcerative colitis trial, PMID 23879825 ran a randomized trial of HBOT added to standard care in severe ulcerative colitis flares. HBOT did not improve outcomes over standard care alone.
The Chen and colleagues 2021 systematic review and meta-analysis, PMC 8290506 pooled the ulcerative colitis HBOT data. The pooled effect for severe UC was small and inconsistent. The reviewers flagged risk of bias.
A 2022 meta-analysis on HBOT in IBD, PMID 35100179 reviewed the broader IBD HBOT base. The signal for perianal Crohn's fistulas was the strongest. Broader colitis benefit was not supported.
A 2022 narrative review on HBOT in IBD, PMC 8130665 reached a similar split. Perianal Crohn's fistulas may benefit. Broader colitis use lacks support.
The 2022 hyperbaric oxygen as monotherapy in a UC flare case report showed clinical interest but isolated case reports do not change practice.
The HBOT-UC consortium 2024 study design paper, PMID 39403018 lays out NIDDK's funded effort to test HBOT in severe UC flares. Results are pending. Until they land, severe UC HBOT remains investigational without strong support.
The pattern is more nuanced than other off-label uses. One specific subset — therapy-refractory perianal fistulas in Crohn's — has a real signal from one small pilot. Broader IBD applications do not have that backing.
Why people pursue this anyway
IBD is a chronic condition that can hit quality of life hard. Perianal fistula in Crohn's is one of the hardest forms to manage. Drugs and surgery often fail or only partly help.
That care gap is real. Patients with refractory perianal Crohn's reading the Lansdorp 2022 results see a small but hopeful pilot. The marketing pull is easy to see.
For severe colitis flares, the marketing is harder to defend. The Pagoldh 2013 randomized trial was negative. Patients should know that before paying for a course.
Wellness chains including Restore Hyper Wellness and many small clinics market HBOT to general IBD patients. The honest framing is that perianal Crohn's may benefit, but most other IBD applications do not have that support.
For deeper context, see our evidence-vs-marketing breakdown of the leading HBOT chain and our analysis of institutional silence on HBOT.
What GI guidelines actually say
The American Gastroenterological Association IBD guides do not list HBOT as a standard option. The European Crohn's and Colitis Organisation also does not list HBOT.
The picture may evolve. Perianal Crohn's fistula data from the HOT-TOPIC trial has spurred follow-up research. Larger randomized trials are needed before any specialty body would update its guidelines.
UHMS does not list IBD on its 14 approved indications. The UHMS HBO indications page, 2024 is the source of truth.
Major academic IBD centers do not routinely offer HBOT for IBD. A few research centers run HBOT in IBD trials. Most wound care and dive medicine chambers run for the approved uses only.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $12,000. Premium chain packages can run higher.
Patients face this cost without insurance support. HSA and FSA accounts may or may not accept the claim, depending on plan rules.
For refractory perianal Crohn's, the math is closer. The HOT-TOPIC pilot showed real gains in patients who had failed other options. For broader IBD uses, the math is much weaker.
The framing is not that no patient should try this. The framing is that the evidence varies by subset — and only one subset has a clean signal.
What to ask your GI doctor
Patients weighing HBOT for IBD can ask a few key questions. Each cuts through clinic marketing.
What specific IBD subset is being studied — perianal Crohn's has the cleanest signal. What did the Pagoldh 2013 UC trial show — the answer is "no benefit over standard care." Are there active larger trials I could join — the HBOT-UC consortium is one option for severe UC.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The HOT-TOPIC protocol used medical-grade hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft 1.3 ATA chambers from OxyHealth or Summit to Sea at many wellness sites.
Distinguishing from FDA-approved uses
IBD sits in a different spot from approved HBOT uses. The approved list — CO poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten more — all have decades of backing data and multi-center trials.
Our diabetic foot ulcer evidence atlas and carbon monoxide poisoning evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, settled mechanism, insurance coverage.
IBD has emerging interest. The perianal Crohn's subset shows real promise but needs larger randomized trials, while broader IBD use is not yet supported. The honest call is "investigational with one promising subset" rather than "settled treatment."
Frequently asked questions
Is HBOT FDA-approved for IBD?
No. The FDA recognizes 14 conditions for HBOT and IBD is not among them. The UHMS approved indications list, current 2024, also does not include IBD.
What did the HOT-TOPIC trial show?
The Lansdorp HOT-TOPIC pilot studied 20 Crohn's patients with refractory perianal fistulas. At week 16, the perianal disease score dropped in 13 of 20 patients to inactive levels. One-year follow-up showed clinical and radiologic gains held, but biochemical and quality-of-life gains did not.
Does HBOT help severe ulcerative colitis flares?
The Pagoldh 2013 randomized trial said no. Adding HBOT to standard care did not improve outcomes over standard care alone in severe colitis flares. The NIDDK-funded HBOT-UC consortium is running a larger trial.
Will Medicare or insurance cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. IBD is out-of-pocket at almost all clinics offering this protocol.
How much does a course cost?
Most wellness clinics charge $200 to $350 per session. A 40-session course runs $6,000 to $12,000. Premium chain packages can run higher.
Sources
- Dulai systematic review 2014, PMID 24738651
- Lansdorp HOT-TOPIC pilot 2021, PMID 35146959
- Lansdorp HOT-TOPIC one-year follow-up 2022
- Pagoldh ulcerative colitis trial 2013, PMID 23879825
- Chen UC HBOT meta-analysis 2021
- IBD HBOT meta-analysis 2022, PMID 35100179
- Narrative review on HBOT in IBD 2022, PMC 8130665
- HBOT-UC consortium design paper 2024, PMID 39403018
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for inflammatory bowel disease is an investigational off-label use without FDA approval. The strongest signal is in therapy-refractory perianal Crohn's fistulas from one small pilot. Standard IBD care including biologics, immunomodulators, and surgery remains the guideline-recommended path. Talk to your GI doctor before pursuing any out-of-pocket HBOT protocol. This page does not diagnose, treat, or substitute for professional medical care.